Histone Lysine Lactylation (Kla)‐induced BCAM Promotes OSCC Progression and Cis‐Platinum Resistance
Oral Diseases · 2025
DOI: 10.1111/odi.15179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Guangzhao Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Cent…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Mouth Neoplasms, Histones, Cisplatin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: the Postdoctoral Fellowship Program of CPSF, the Exploration and Research Project of West China Hospital of Stomatology, Sichuan University.
Abstract (Originalsprache)
Objective
Histone lysine lactylation (Kla) plays a vital role in cancer progression. However, the prognostic value of histone Kla in oral squamous cell carcinoma (OSCC) remains unclear. Materials and Methods OSCC RNA expression data were obtained from the TCGA and GEO databases. We explored the prognostic value of histone Kla in OSCC via constructing a Cox model and determined the role of Kla in OSCC drug susceptibility and tumor microenvironment (TME). In addition, the biological roles of candidate biomarkers were identified.
Results
A total of 1223 Kla‐specific genes were obtained, with 228 DEKlaGs in OSCC. GO and KEGG enrichment analyses suggested that DEKlaGs contributed to inflammatory and cancer progression. A Cox model in accordance with BCAM , CGNL1 , DGKG , and OLR1 could predict OSCC patient prognosis accurately. Subsequently, Kla‐induced prognostic genes were identified to play a crucial role in OSCC drug therapy and TME. Moreover, BCAM was identified as a biomarker that promoted OSCC invasion, angiogenesis, and chemotherapy resistance.
Conclusion
Kla was identified to be associated with OSCC prognosis, drug therapy, and TME. Histone Kla‐induced BCAM was identified to play a crucial role during OSCC progression, suggesting that Kla is promising to be a novel therapeutic target for OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Center for Dental Medicine Plus, Department of Head and Neck Oncology, Wes…
- Department of Dentistry, The Second people's Hospital of Tibet Autonomous Region, Xizang, China.
ORCID-Profile: Guangzhao Huang
Förderung
- the Postdoctoral Fellowship Program of CPSF
- the Exploration and Research Project of West China Hospital of Stomatology, Sichuan University
Zitieren
APA
Huang, G., Chen, S., He, J., Li, H., Ma, Z., Lubamba, G. P., Wang, L., Guo, Z., & Li, C. (2025). Histone Lysine Lactylation (Kla)‐induced BCAM Promotes OSCC Progression and Cis‐Platinum Resistance. Oral Diseases. https://doi.org/10.1111/odi.15179
Vancouver
Huang G, Chen S, He J, Li H, Ma Z, Lubamba GP, et al. Histone Lysine Lactylation (Kla)‐induced BCAM Promotes OSCC Progression and Cis‐Platinum Resistance. Oral Diseases. 2025. doi:10.1111/odi.15179
BibTeX
@article{Huang2025,
author = {Huang, Guangzhao and Chen, Su and He, Jialu and Li, Honglin and Ma, Zhongkai and Lubamba, Grace Paka and Wang, Lei and Guo, Zhiyong and Li, Chunjie},
title = {Histone Lysine Lactylation (Kla)‐induced BCAM Promotes OSCC Progression and Cis‐Platinum Resistance},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15179}
}
EUVIMED